This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to sermorelin through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
You sleep eight hours and wake up tired. You train consistently and recover slower every year. Your doctor says your labs are normal. For many adults over 40, that disconnect traces to a hormone axis that standard bloodwork rarely evaluates: the growth hormone cascade, and the pituitary's declining ability to sustain it.
Sermorelin is a synthetic peptide designed to reactivate that axis. Here is how it works, what the research shows, and how to know whether it is relevant to you.
Key Takeaways
- Regulatory Status: FDA-approved in 1997 for pediatric growth hormone deficiency; voluntary market withdrawal occurred by 2008. Not currently FDA-approved for adult use. Available as a compounded prescription through licensed providers and licensed 503A compounding pharmacies.
- Research Stage: Clinically studied in the GHRH secretagogue class; available through compounding
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View compound reference data (PubChem CID 16132413) — FDA approval lapsed 2008; no current DailyMed label
- How it works: Binds GHRH receptors on the anterior pituitary, stimulating pulsatile growth hormone release while preserving the body's natural feedback loop.
- What the research shows: GHRH class trials associate receptor activation with reduced visceral fat, improved lean mass, and higher IGF-1 over 3–6 months.
What Is Sermorelin?
Sermorelin acetate is a synthetic 29-amino-acid peptide identical to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary, triggering pulsatile growth hormone release while preserving the hypothalamic feedback loop that prevents supraphysiological GH levels (background on somatostatin modulation of GHRH pathways supports this regulatory mechanism). This physiological braking mechanism is what distinguishes it from direct exogenous human growth hormone (HGH).
Sermorelin was first characterized in the early 1980s and received FDA approval in 1997 for the diagnosis and treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the product from the US market by 2008, not because of safety findings, but due to commercial factors, including the availability of longer-acting GHRH analogs. No current FDA-approved sermorelin product exists. Compounding pharmacies may prepare sermorelin under Section 503A with a patient-specific prescription, and it remains one of the most commonly prescribed GHRH analogs in the compounding market.
Sermorelin and the GHRH Class Evidence
Sermorelin's clinical evidence base is inseparable from a closely related compound: tesamorelin. Tesamorelin is a GHRH analog with an added trans-3-hexenoic acid group that extends its plasma half-life. It is FDA-approved for HIV-associated lipodystrophy and has the strongest controlled trial data of any GHRH analog. Both compounds bind the same GHRH receptor on the anterior pituitary and operate through the same pulsatile GH release mechanism. Where sermorelin-specific data are limited, the tesamorelin evidence base provides the most relevant reference point for understanding what GHRH receptor activation can achieve. The distinction is noted throughout this article where it applies.
What Sermorelin May Support
1. Body Composition: Visceral Fat Reduction
Growth hormone drives lipolysis, particularly in visceral adipose tissue. GHRH receptor activation stimulates pulsatile GH release, which in turn promotes fatty acid mobilization from abdominal fat stores. The controlled trial evidence for this effect comes from the GHRH class: a 2007 RCT by Falutz and colleagues in the New England Journal of Medicine randomized 412 HIV-infected patients to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks and found that visceral adipose tissue decreased by 10.9% in the tesamorelin group versus 0.6% with placebo (p < 0.0001), with a concurrent 51 mg/dL reduction in triglycerides (p < 0.001 vs. baseline). A 2010 pooled analysis by the same team in JCEM combined two phase 3 trials (N=806; tesamorelin 2 mg subcutaneous daily vs. placebo, 2:1 randomization, 26-week primary phase with 26-week extension) and found visceral adipose tissue reduced by approximately 15.4% at 26 weeks versus placebo, sustained through 52 weeks without significant glucose perturbation. A 2012 RCT by Makimura and colleagues in JCEM randomized 60 abdominally obese adults with reduced GH secretion to tesamorelin 2 mg subcutaneous daily or placebo for 12 months and found a net 19% reduction in visceral adipose tissue versus placebo, alongside a net 6% improvement in carotid intima-media thickness, a net triglyceride reduction of 38 mg/dL versus placebo (-26 ± 16 vs. +12 ± 8 mg/dL), and a significant reduction in log CRP (-0.17 ± 0.04 vs. -0.03 ± 0.05 mg/L), without aggravating glucose. These trials used tesamorelin; sermorelin activates the same receptor but controlled sermorelin-specific body composition data remain limited.
2. Lean Muscle Mass and Physical Function
GH stimulates protein synthesis by promoting amino acid uptake (as noted in an editorial commentary on GH signaling) and IGF-1 secretion; IGF-1 in turn activates mTOR signaling in muscle tissue. These pathways are engaged by any compound that restores pulsatile GH release through the GHRH receptor. A 2019 secondary analysis by Adrian and colleagues in the Journal of Frailty and Aging examined CT scans from 341 HIV-infected adults (193 tesamorelin responders, 148 placebo) who received tesamorelin 2 mg subcutaneous daily for 26 weeks and found that tesamorelin significantly increased truncal muscle density by 1.56 to 4.86 Hounsfield units across four muscle groups versus placebo (all p < 0.005), with concurrent increases in lean muscle area of 0.64 to 1.08 cm² across four truncal muscle groups versus placebo. A 2026 meta-analysis by Badran and Helal in Obesity Research and Clinical Practice, pooling five RCTs of tesamorelin 2 mg subcutaneous daily versus placebo over 26 to 52 weeks, confirmed a significant increase in lean body mass (mean difference 1.42 kg, 95% CI 1.13–1.71, p < 0.001) alongside reductions in visceral adipose tissue, trunk fat, and hepatic fat without serious adverse effects or glucose perturbation. As with body composition, these findings come from tesamorelin trials; the shared receptor mechanism supports biological plausibility for sermorelin but direct extrapolation requires that caveat.
3. IGF-1 Levels and GH Axis Function
Age-related decline in endogenous hypothalamic GHRH output is the primary driver of somatopause — the gradual reduction in GH secretion seen after the third decade, as a 1999 study by Russell-Aulet and Jaffe in JCEM established. A 1989 study by Iovino, Monteleone, and Steardo in JCEM administered 100 mcg intravenous GHRH-40 every 2 days for 12 days to 7 healthy men aged 65–78 in a double-blind placebo-controlled design, finding that this priming regimen significantly restored GH pulse amplitude at 30, 60, and 90 minutes after an acute GHRH challenge compared to values seen after placebo priming — notable given that baseline peak GH in the elderly group was only 3.1 ± 1.0 ng/mL versus 21.6 ± 5.0 ng/mL in young controls — supporting the rationale for exogenous GHRH analog use. A 2017 retrospective study by Sigalos and Pastuszak reviewed 14 hypogonadal men (mean age 33.2 years) on testosterone therapy who received a combination of GHRP-2, GHRP-6, and sermorelin at 100 mcg three times daily for a mean of 134 days, finding that serum IGF-1 levels rose from a baseline of 159.5 ng/mL to 239.0 ng/mL — a 50% increase (p < 0.0001). The 1999 sermorelin monograph in BioDrugs by Prakash and Goa confirms this mechanism for sermorelin specifically.
4. Sleep Architecture and Slow-Wave Sleep
GHRH has documented sleep-promoting effects in controlled studies. A 1993 study in the American Journal of Physiology by Kerkhofs and Van Cauter administered intravenous GHRH at 0.3 mcg/kg to 8 healthy young men in a crossover design and found that GHRH given during late sleep produced an almost 10-fold increase in slow-wave sleep versus placebo, without disrupting sleep continuity. A separate 1992 study in Neuroendocrinology by Steiger and colleagues administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 7 healthy men and found that slow-wave sleep increased from 14.0% to 20.2% of total sleep time (a 44% relative increase versus placebo) alongside elevated nocturnal GH secretion and blunted cortisol release. A 1999 study in Psychoneuroendocrinology by Perras and Marshall administered 300 mcg intranasal GHRH versus placebo in a double-blind crossover design to 12 young and 11 elderly healthy men and found that intranasal GHRH increased both slow-wave sleep and REM sleep — concentrated in the second half of the night — with concurrent modulation of cortisol and GH secretion, and these effects did not depend on subject age. A 1997 study in Neurobiology of Aging by Guldner and Schier administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 13 healthy seniors (mean age 69.3 years) and found significantly reduced nocturnal awakenings and a longer first non-REM sleep period compared to placebo, though the magnitude of these effects was substantially attenuated relative to young adults tested with the same protocol, consistent with age-related decline in GHRH receptor sensitivity. The relationship between GH pulsatility and slow-wave sleep is bidirectional: GH is primarily secreted during slow-wave sleep, and GHRH signaling may promote both.
5. Triglyceride and Lipid Profile Effects
GH influences lipid metabolism through two primary pathways: promoting lipolysis in adipose tissue and affecting hepatic very-low-density lipoprotein (VLDL) production. Restoring pulsatile GH release through GHRH receptor activation engages both. In the GHRH class trials, the Makimura JCEM RCT found significant reductions in triglycerides and CRP compared to placebo, and the Falutz NEJM trial observed favorable lipid changes alongside body composition improvements. These data come from tesamorelin; sermorelin-specific lipid trial data remain limited, though the shared mechanism supports biological plausibility.
Sermorelin vs. Exogenous HGH: Key Differences
Sermorelin stimulates the body's own GH production; exogenous HGH bypasses the pituitary entirely. This distinction preserves the negative feedback loop that prevents excess GH levels.
When HGH is injected directly, it elevates GH levels regardless of what the hypothalamic-pituitary axis is signaling. There is no physiological ceiling. Supraphysiological GH exposure is associated with adverse effects including fluid retention, joint pain, potential insulin resistance, and long-term risk considerations. Sermorelin works upstream: it prompts the pituitary to release GH in its natural pulsatile pattern, and the hypothalamus retains the ability to reduce that signal via somatostatin (research on somatostatin modulation provides context for this feedback pathway) when levels are sufficient. This regulatory architecture limits the risk of runaway GH elevation.
Practically, sermorelin requires an intact and responsive pituitary. Individuals with significant pituitary damage or primary GH deficiency confirmed by stimulation testing may not respond adequately. Exogenous HGH bypasses this requirement. HGH is FDA-approved for adult GH deficiency confirmed by stimulation testing; sermorelin has no current FDA-approved adult indication. In the compounding context, sermorelin is typically preferred over exogenous HGH for age-related GH decline precisely because of its physiological mechanism and preserved feedback regulation. As of April 2026, all GH secretagogues — including sermorelin — are on the WADA Prohibited List for use in competition.
Sermorelin Formulations
Superpower offers sermorelin in two compounded forms. Subcutaneous injection is the most bioavailable delivery method. Injections are typically administered in the evening to align with the body's natural nocturnal GH pulse, which peaks during slow-wave sleep. Sublingual troches, dissolved under the tongue, provide a needle-free alternative with lower but sustained absorption. Bioavailability via the sublingual route is lower than subcutaneous injection; providers may adjust dosing accordingly. A 1986 dose-response study by Vance and Evans in Clinical Pharmacology and Therapeutics tested [Nle27]GHRH(1-29)-NH2 in healthy men (N=10 intravenous, N=8 subcutaneous, N=5 intranasal) across intravenous doses of 0.25 to 10 mcg/kg, subcutaneous doses, and intranasal doses up to 50 mcg/kg and found that intravenous delivery at 1–2 mcg/kg produced maximal GH peaks of approximately 90 mU/L, while intranasal delivery required roughly 50-fold higher doses to match that response due to 3–5% mucosal bioavailability versus injection. Providers determine the appropriate formulation based on clinical context, patient preference, and therapeutic objectives.
Biomarkers to Monitor With Sermorelin
A licensed provider will determine appropriate monitoring. The following biomarkers are clinically relevant to sermorelin's mechanism, therapeutic effects, and safety profile:
- IGF-1 (Insulin-Like Growth Factor 1): The primary downstream marker of GH axis activity. IGF-1 is the standard benchmark for evaluating GH secretagogue response and is the core monitoring marker during sermorelin therapy. Providers typically assess at baseline and at 3 and 6 months. An age-adjusted reading below the reference range supports the clinical rationale for therapy.
- Fasting glucose: GH has counter-regulatory effects on insulin signaling; elevated GH can reduce insulin sensitivity. Fasting glucose at baseline and during therapy identifies individuals at elevated metabolic risk. The GHRH class trials found no significant glucose perturbation at therapeutic doses, but individual monitoring remains standard practice.
- HbA1c: A longer-term glycemic marker that complements fasting glucose. Relevant for individuals with pre-existing insulin resistance or elevated fasting glucose at baseline. Providers typically assess at baseline and at 6 months. HbA1c captures average glucose exposure over approximately 3 months, providing a broader metabolic picture than a single fasting reading.
- Fasting insulin: Evaluates insulin sensitivity independent of glucose alone. Elevated fasting insulin at baseline may indicate underlying insulin resistance that warrants consideration before initiating GH-modulating therapy.
- Triglycerides: GHRH analog trials have documented favorable triglyceride effects. Baseline and follow-up triglyceride levels provide an objective reference for lipid response to therapy.
- hs-CRP: A sensitive marker of systemic inflammation. The Makimura trial found reductions in CRP with GHRH analog use. Baseline hs-CRP establishes whether elevated inflammatory status is present before therapy begins.
- Complete metabolic panel (CMP): Covers liver enzymes (AST, ALT, ALP), kidney function (BUN, creatinine), and electrolytes. Elevated liver enzymes or impaired renal function may affect prescribing decisions. Providers typically assess at baseline.
- Complete blood count (CBC): Establishes baseline hematologic status. GH axis activity can influence erythropoiesis (as discussed in an editorial on GH physiology); CBC provides a reference point for any changes in red cell parameters during therapy.
- Total and free testosterone (men): GH and IGF-1 interact with the hypothalamic-pituitary-gonadal axis. Providers often assess baseline testosterone alongside IGF-1 when evaluating adult males with symptoms of hormonal decline.
IGF-1, fasting glucose, and a complete metabolic panel are the core markers for evaluating GH axis function before and during sermorelin therapy. Establishing these baselines makes changes at 3 and 6 months measurable. A provider will determine the appropriate scope of monitoring based on individual history and concurrent medications.
What Sermorelin Is Typically Prescribed For
Providers typically evaluate sermorelin candidates based on IGF-1 levels below the age-adjusted reference range, alongside symptoms consistent with adult GH decline: reduced lean mass, increased visceral fat, poor sleep quality, and slow recovery from exercise. A 2025 review by Fernandez-Garza and Guillen-Silva in Frontiers in Aging summarizes the rationale and the evidence gaps, noting that GH axis modulation shows anti-aging potential but that long-term safety and efficacy in healthy aging adults remain areas of active research. Baseline blood work confirming low IGF-1 is the standard starting point. Sermorelin requires a prescription from a licensed provider and is not available over the counter.
Who Should Not Use Sermorelin
A licensed provider will evaluate individual risk factors before prescribing. The following are generally considered contraindications or conditions requiring additional clinical scrutiny:
- Active malignancy or personal history of cancer — GH's pro-proliferative signaling may theoretically stimulate cell growth; sermorelin use has not been studied in active cancer populations
- Diabetes mellitus or clinically significant insulin resistance — GH counter-regulates insulin; elevated GH can worsen glycemic control in susceptible individuals
- Active intracranial lesions or a history of pituitary tumor — sermorelin's pituitary-stimulating mechanism requires clinical evaluation in this context
- Pregnancy or breastfeeding — safety in these populations has not been established
- Known hypersensitivity to sermorelin acetate, mannitol (a common excipient in compounded formulations), or any component of the formulation
- Hypothyroidism, if untreated — thyroid hormone is required for adequate GH response; providers typically evaluate thyroid status before initiating sermorelin therapy
Side Effects and Safety Considerations
The sermorelin safety profile is characterized primarily in the 1999 Prakash and Goa monograph and in GHRH class studies. Most reported adverse effects are mild, dose-dependent, and often diminish within the first weeks of use.
Common (reported in clinical studies):
- Injection-site redness, swelling, or pain — typically resolves within 30 to 60 minutes of subcutaneous administration
- Flushing — transient and generally mild; more common at higher doses
- Headache — reported in early-stage use; often resolves spontaneously
- Somnolence or drowsiness — consistent with sermorelin's sleep-promoting mechanism; generally considered favorable when timed to evening administration
Less common but reported:
- Fluid retention or peripheral edema — attributable to GH's effects on sodium and water reabsorption; monitor in individuals with cardiovascular or renal conditions
- Joint pain or stiffness (arthralgia) — associated with GH axis activity; generally dose-related and reversible on dose adjustment
- Dizziness — contact your provider if persistent
- Glucose elevation — particularly in individuals with pre-existing insulin resistance; baseline and follow-up glucose monitoring is standard
Is Sermorelin Legal?
As of April 2026, sermorelin is not FDA-approved for any indication. The original pediatric approval lapsed after the manufacturer voluntarily withdrew the product from the US market by 2008. No current FDA-reviewed clinical indication exists. Sermorelin is not available over the counter.
Sermorelin is on the FDA's Category 1 bulk drug substances list, meaning it is eligible for compounding. It may be legally compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy with a patient-specific prescription. Superpower facilitates access to compounded sermorelin through its licensed provider network and compounding pharmacy partners.
As of the 2026 WADA Prohibited List, all growth hormone secretagogues — including GHRH analogs — are prohibited in competition. Athletes subject to anti-doping testing should consult their governing body or a qualified anti-doping advisor before use.
Understanding Your Baseline Before Starting Sermorelin
A single IGF-1 reading does not tell the full story. Baseline testing establishes where your GH axis sits before therapy begins, so changes at 3 and 6 months are measurable and interpretable. IGF-1 below the age-adjusted reference range confirms that the GH axis is underperforming relative to age-matched norms. Fasting glucose and a complete metabolic panel identify metabolic risk factors that inform prescribing decisions. Without these baselines, there is no objective way to evaluate whether therapy is producing a meaningful response, or whether individual risk factors require closer monitoring.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not in symptoms alone.
Frequently Asked Questions
What is the difference between sermorelin and HGH?
Sermorelin stimulates the pituitary to release growth hormone in a pulsatile, physiologically regulated pattern. Exogenous HGH delivers GH directly, bypassing the hypothalamic-pituitary feedback loop entirely. This means HGH can produce supraphysiological GH levels without a natural braking mechanism. Sermorelin preserves that feedback regulation, which limits the risk of excess GH exposure. HGH is FDA-approved for confirmed adult GH deficiency; sermorelin has no current FDA-approved adult indication and is available only through compounding.
Does sermorelin suppress natural growth hormone production?
No. Sermorelin operates by stimulating the pituitary's own GH release, not by supplying exogenous GH. Because it preserves the hypothalamic feedback loop, the body retains the ability to reduce GH output via somatostatin when levels are adequate. This physiological self-regulation distinguishes sermorelin from exogenous HGH, which can suppress the pituitary's natural output over time through negative feedback from circulating GH and IGF-1.
How long does sermorelin take to work?
IGF-1 levels typically begin to rise within several weeks of consistent use. Measurable changes in body composition, sleep quality, and recovery are generally reported at 3 to 6 months. Response varies based on baseline IGF-1 levels, pituitary responsiveness, and individual physiology. Individuals with lower baseline IGF-1 tend to show the most pronounced response.
Do sermorelin injections or troches work better?
Subcutaneous injections offer higher bioavailability and more consistent GH stimulation. Sublingual troches are a needle-free alternative with lower but sustained absorption. Clinical evidence for the GHRH class is based primarily on injectable formulations; sublingual data are more limited. The appropriate formulation depends on clinical context, patient preference, and provider assessment.
How long can you stay on sermorelin?
There is no established maximum duration for compounded sermorelin use. GHRH analog studies have evaluated therapy over periods of 26 to 52 weeks. Providers typically reassess at 3- to 6-month intervals based on IGF-1 response, symptom changes, and metabolic markers. Long-term safety in healthy aging adults is an ongoing area of research. Continued use requires periodic provider evaluation and ongoing prescription.
Is sermorelin FDA-approved?
Sermorelin was FDA-approved in 1997 for the diagnosis and treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the product from the US market by 2008. There is no currently FDA-approved sermorelin product. As of April 2026, sermorelin is available only as a compounded prescription through licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider.
What age should you start sermorelin?
There is no universally established minimum age for compounded sermorelin use in adults. Providers typically evaluate candidacy based on clinical presentation and biomarker findings rather than age alone. Age-related GH decline (somatopause) begins in the third decade. Many providers who prescribe sermorelin see patients in their 40s and 50s with documented low IGF-1 alongside symptoms consistent with GH decline. A baseline assessment including IGF-1 and metabolic markers is the appropriate starting point.
IMPORTANT SAFETY INFORMATION
Sermorelin is not currently FDA-approved for any indication. It was FDA-approved in 1997 for pediatric growth hormone deficiency; the manufacturer voluntarily withdrew the product by 2008 due to commercial factors. Sermorelin is on the FDA's Category 1 bulk drug substances list and may be legally compounded under Section 503A. Clinical evidence cited on this page draws primarily from the GHRH analog class (including tesamorelin trials); results may not be directly transferable to compounded sermorelin. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: active malignancy or cancer history; diabetes or significant insulin resistance; active intracranial lesions or pituitary tumor history; pregnancy and breastfeeding; untreated hypothyroidism; known hypersensitivity to sermorelin or mannitol.
Common side effects: injection site redness/swelling, flushing, headache, drowsiness.
Less common: fluid retention or edema, joint pain (arthralgia), dizziness, glucose elevation in individuals with pre-existing insulin resistance.
All growth hormone secretagogues are on the 2026 WADA Prohibited List for use in competition.
This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to sermorelin through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription compound.
You sleep eight hours and wake up tired. You train consistently and recover slower every year. Your doctor says your labs are normal. For many adults over 40, that disconnect traces to a hormone axis that standard bloodwork rarely evaluates: the growth hormone cascade, and the pituitary's declining ability to sustain it.
Sermorelin is a synthetic peptide designed to reactivate that axis. Here is how it works, what the research shows, and how to know whether it is relevant to you.
Key Takeaways
- Regulatory Status: FDA-approved in 1997 for pediatric growth hormone deficiency; voluntary market withdrawal occurred by 2008. Not currently FDA-approved for adult use. Available as a compounded prescription through licensed providers and licensed 503A compounding pharmacies.
- Research Stage: Clinically studied in the GHRH secretagogue class; available through compounding
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: View compound reference data (PubChem CID 16132413) — FDA approval lapsed 2008; no current DailyMed label
- How it works: Binds GHRH receptors on the anterior pituitary, stimulating pulsatile growth hormone release while preserving the body's natural feedback loop.
- What the research shows: GHRH class trials associate receptor activation with reduced visceral fat, improved lean mass, and higher IGF-1 over 3–6 months.
What Is Sermorelin?
Sermorelin acetate is a synthetic 29-amino-acid peptide identical to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on the anterior pituitary, triggering pulsatile growth hormone release while preserving the hypothalamic feedback loop that prevents supraphysiological GH levels (background on somatostatin modulation of GHRH pathways supports this regulatory mechanism). This physiological braking mechanism is what distinguishes it from direct exogenous human growth hormone (HGH).
Sermorelin was first characterized in the early 1980s and received FDA approval in 1997 for the diagnosis and treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the product from the US market by 2008, not because of safety findings, but due to commercial factors, including the availability of longer-acting GHRH analogs. No current FDA-approved sermorelin product exists. Compounding pharmacies may prepare sermorelin under Section 503A with a patient-specific prescription, and it remains one of the most commonly prescribed GHRH analogs in the compounding market.
Sermorelin and the GHRH Class Evidence
Sermorelin's clinical evidence base is inseparable from a closely related compound: tesamorelin. Tesamorelin is a GHRH analog with an added trans-3-hexenoic acid group that extends its plasma half-life. It is FDA-approved for HIV-associated lipodystrophy and has the strongest controlled trial data of any GHRH analog. Both compounds bind the same GHRH receptor on the anterior pituitary and operate through the same pulsatile GH release mechanism. Where sermorelin-specific data are limited, the tesamorelin evidence base provides the most relevant reference point for understanding what GHRH receptor activation can achieve. The distinction is noted throughout this article where it applies.
What Sermorelin May Support
1. Body Composition: Visceral Fat Reduction
Growth hormone drives lipolysis, particularly in visceral adipose tissue. GHRH receptor activation stimulates pulsatile GH release, which in turn promotes fatty acid mobilization from abdominal fat stores. The controlled trial evidence for this effect comes from the GHRH class: a 2007 RCT by Falutz and colleagues in the New England Journal of Medicine randomized 412 HIV-infected patients to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks and found that visceral adipose tissue decreased by 10.9% in the tesamorelin group versus 0.6% with placebo (p < 0.0001), with a concurrent 51 mg/dL reduction in triglycerides (p < 0.001 vs. baseline). A 2010 pooled analysis by the same team in JCEM combined two phase 3 trials (N=806; tesamorelin 2 mg subcutaneous daily vs. placebo, 2:1 randomization, 26-week primary phase with 26-week extension) and found visceral adipose tissue reduced by approximately 15.4% at 26 weeks versus placebo, sustained through 52 weeks without significant glucose perturbation. A 2012 RCT by Makimura and colleagues in JCEM randomized 60 abdominally obese adults with reduced GH secretion to tesamorelin 2 mg subcutaneous daily or placebo for 12 months and found a net 19% reduction in visceral adipose tissue versus placebo, alongside a net 6% improvement in carotid intima-media thickness, a net triglyceride reduction of 38 mg/dL versus placebo (-26 ± 16 vs. +12 ± 8 mg/dL), and a significant reduction in log CRP (-0.17 ± 0.04 vs. -0.03 ± 0.05 mg/L), without aggravating glucose. These trials used tesamorelin; sermorelin activates the same receptor but controlled sermorelin-specific body composition data remain limited.
2. Lean Muscle Mass and Physical Function
GH stimulates protein synthesis by promoting amino acid uptake (as noted in an editorial commentary on GH signaling) and IGF-1 secretion; IGF-1 in turn activates mTOR signaling in muscle tissue. These pathways are engaged by any compound that restores pulsatile GH release through the GHRH receptor. A 2019 secondary analysis by Adrian and colleagues in the Journal of Frailty and Aging examined CT scans from 341 HIV-infected adults (193 tesamorelin responders, 148 placebo) who received tesamorelin 2 mg subcutaneous daily for 26 weeks and found that tesamorelin significantly increased truncal muscle density by 1.56 to 4.86 Hounsfield units across four muscle groups versus placebo (all p < 0.005), with concurrent increases in lean muscle area of 0.64 to 1.08 cm² across four truncal muscle groups versus placebo. A 2026 meta-analysis by Badran and Helal in Obesity Research and Clinical Practice, pooling five RCTs of tesamorelin 2 mg subcutaneous daily versus placebo over 26 to 52 weeks, confirmed a significant increase in lean body mass (mean difference 1.42 kg, 95% CI 1.13–1.71, p < 0.001) alongside reductions in visceral adipose tissue, trunk fat, and hepatic fat without serious adverse effects or glucose perturbation. As with body composition, these findings come from tesamorelin trials; the shared receptor mechanism supports biological plausibility for sermorelin but direct extrapolation requires that caveat.
3. IGF-1 Levels and GH Axis Function
Age-related decline in endogenous hypothalamic GHRH output is the primary driver of somatopause — the gradual reduction in GH secretion seen after the third decade, as a 1999 study by Russell-Aulet and Jaffe in JCEM established. A 1989 study by Iovino, Monteleone, and Steardo in JCEM administered 100 mcg intravenous GHRH-40 every 2 days for 12 days to 7 healthy men aged 65–78 in a double-blind placebo-controlled design, finding that this priming regimen significantly restored GH pulse amplitude at 30, 60, and 90 minutes after an acute GHRH challenge compared to values seen after placebo priming — notable given that baseline peak GH in the elderly group was only 3.1 ± 1.0 ng/mL versus 21.6 ± 5.0 ng/mL in young controls — supporting the rationale for exogenous GHRH analog use. A 2017 retrospective study by Sigalos and Pastuszak reviewed 14 hypogonadal men (mean age 33.2 years) on testosterone therapy who received a combination of GHRP-2, GHRP-6, and sermorelin at 100 mcg three times daily for a mean of 134 days, finding that serum IGF-1 levels rose from a baseline of 159.5 ng/mL to 239.0 ng/mL — a 50% increase (p < 0.0001). The 1999 sermorelin monograph in BioDrugs by Prakash and Goa confirms this mechanism for sermorelin specifically.
4. Sleep Architecture and Slow-Wave Sleep
GHRH has documented sleep-promoting effects in controlled studies. A 1993 study in the American Journal of Physiology by Kerkhofs and Van Cauter administered intravenous GHRH at 0.3 mcg/kg to 8 healthy young men in a crossover design and found that GHRH given during late sleep produced an almost 10-fold increase in slow-wave sleep versus placebo, without disrupting sleep continuity. A separate 1992 study in Neuroendocrinology by Steiger and colleagues administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 7 healthy men and found that slow-wave sleep increased from 14.0% to 20.2% of total sleep time (a 44% relative increase versus placebo) alongside elevated nocturnal GH secretion and blunted cortisol release. A 1999 study in Psychoneuroendocrinology by Perras and Marshall administered 300 mcg intranasal GHRH versus placebo in a double-blind crossover design to 12 young and 11 elderly healthy men and found that intranasal GHRH increased both slow-wave sleep and REM sleep — concentrated in the second half of the night — with concurrent modulation of cortisol and GH secretion, and these effects did not depend on subject age. A 1997 study in Neurobiology of Aging by Guldner and Schier administered four pulsatile 50 mcg intravenous boluses of GHRH versus placebo to 13 healthy seniors (mean age 69.3 years) and found significantly reduced nocturnal awakenings and a longer first non-REM sleep period compared to placebo, though the magnitude of these effects was substantially attenuated relative to young adults tested with the same protocol, consistent with age-related decline in GHRH receptor sensitivity. The relationship between GH pulsatility and slow-wave sleep is bidirectional: GH is primarily secreted during slow-wave sleep, and GHRH signaling may promote both.
5. Triglyceride and Lipid Profile Effects
GH influences lipid metabolism through two primary pathways: promoting lipolysis in adipose tissue and affecting hepatic very-low-density lipoprotein (VLDL) production. Restoring pulsatile GH release through GHRH receptor activation engages both. In the GHRH class trials, the Makimura JCEM RCT found significant reductions in triglycerides and CRP compared to placebo, and the Falutz NEJM trial observed favorable lipid changes alongside body composition improvements. These data come from tesamorelin; sermorelin-specific lipid trial data remain limited, though the shared mechanism supports biological plausibility.
Sermorelin vs. Exogenous HGH: Key Differences
Sermorelin stimulates the body's own GH production; exogenous HGH bypasses the pituitary entirely. This distinction preserves the negative feedback loop that prevents excess GH levels.
When HGH is injected directly, it elevates GH levels regardless of what the hypothalamic-pituitary axis is signaling. There is no physiological ceiling. Supraphysiological GH exposure is associated with adverse effects including fluid retention, joint pain, potential insulin resistance, and long-term risk considerations. Sermorelin works upstream: it prompts the pituitary to release GH in its natural pulsatile pattern, and the hypothalamus retains the ability to reduce that signal via somatostatin (research on somatostatin modulation provides context for this feedback pathway) when levels are sufficient. This regulatory architecture limits the risk of runaway GH elevation.
Practically, sermorelin requires an intact and responsive pituitary. Individuals with significant pituitary damage or primary GH deficiency confirmed by stimulation testing may not respond adequately. Exogenous HGH bypasses this requirement. HGH is FDA-approved for adult GH deficiency confirmed by stimulation testing; sermorelin has no current FDA-approved adult indication. In the compounding context, sermorelin is typically preferred over exogenous HGH for age-related GH decline precisely because of its physiological mechanism and preserved feedback regulation. As of April 2026, all GH secretagogues — including sermorelin — are on the WADA Prohibited List for use in competition.
Sermorelin Formulations
Superpower offers sermorelin in two compounded forms. Subcutaneous injection is the most bioavailable delivery method. Injections are typically administered in the evening to align with the body's natural nocturnal GH pulse, which peaks during slow-wave sleep. Sublingual troches, dissolved under the tongue, provide a needle-free alternative with lower but sustained absorption. Bioavailability via the sublingual route is lower than subcutaneous injection; providers may adjust dosing accordingly. A 1986 dose-response study by Vance and Evans in Clinical Pharmacology and Therapeutics tested [Nle27]GHRH(1-29)-NH2 in healthy men (N=10 intravenous, N=8 subcutaneous, N=5 intranasal) across intravenous doses of 0.25 to 10 mcg/kg, subcutaneous doses, and intranasal doses up to 50 mcg/kg and found that intravenous delivery at 1–2 mcg/kg produced maximal GH peaks of approximately 90 mU/L, while intranasal delivery required roughly 50-fold higher doses to match that response due to 3–5% mucosal bioavailability versus injection. Providers determine the appropriate formulation based on clinical context, patient preference, and therapeutic objectives.
Biomarkers to Monitor With Sermorelin
A licensed provider will determine appropriate monitoring. The following biomarkers are clinically relevant to sermorelin's mechanism, therapeutic effects, and safety profile:
- IGF-1 (Insulin-Like Growth Factor 1): The primary downstream marker of GH axis activity. IGF-1 is the standard benchmark for evaluating GH secretagogue response and is the core monitoring marker during sermorelin therapy. Providers typically assess at baseline and at 3 and 6 months. An age-adjusted reading below the reference range supports the clinical rationale for therapy.
- Fasting glucose: GH has counter-regulatory effects on insulin signaling; elevated GH can reduce insulin sensitivity. Fasting glucose at baseline and during therapy identifies individuals at elevated metabolic risk. The GHRH class trials found no significant glucose perturbation at therapeutic doses, but individual monitoring remains standard practice.
- HbA1c: A longer-term glycemic marker that complements fasting glucose. Relevant for individuals with pre-existing insulin resistance or elevated fasting glucose at baseline. Providers typically assess at baseline and at 6 months. HbA1c captures average glucose exposure over approximately 3 months, providing a broader metabolic picture than a single fasting reading.
- Fasting insulin: Evaluates insulin sensitivity independent of glucose alone. Elevated fasting insulin at baseline may indicate underlying insulin resistance that warrants consideration before initiating GH-modulating therapy.
- Triglycerides: GHRH analog trials have documented favorable triglyceride effects. Baseline and follow-up triglyceride levels provide an objective reference for lipid response to therapy.
- hs-CRP: A sensitive marker of systemic inflammation. The Makimura trial found reductions in CRP with GHRH analog use. Baseline hs-CRP establishes whether elevated inflammatory status is present before therapy begins.
- Complete metabolic panel (CMP): Covers liver enzymes (AST, ALT, ALP), kidney function (BUN, creatinine), and electrolytes. Elevated liver enzymes or impaired renal function may affect prescribing decisions. Providers typically assess at baseline.
- Complete blood count (CBC): Establishes baseline hematologic status. GH axis activity can influence erythropoiesis (as discussed in an editorial on GH physiology); CBC provides a reference point for any changes in red cell parameters during therapy.
- Total and free testosterone (men): GH and IGF-1 interact with the hypothalamic-pituitary-gonadal axis. Providers often assess baseline testosterone alongside IGF-1 when evaluating adult males with symptoms of hormonal decline.
IGF-1, fasting glucose, and a complete metabolic panel are the core markers for evaluating GH axis function before and during sermorelin therapy. Establishing these baselines makes changes at 3 and 6 months measurable. A provider will determine the appropriate scope of monitoring based on individual history and concurrent medications.
What Sermorelin Is Typically Prescribed For
Providers typically evaluate sermorelin candidates based on IGF-1 levels below the age-adjusted reference range, alongside symptoms consistent with adult GH decline: reduced lean mass, increased visceral fat, poor sleep quality, and slow recovery from exercise. A 2025 review by Fernandez-Garza and Guillen-Silva in Frontiers in Aging summarizes the rationale and the evidence gaps, noting that GH axis modulation shows anti-aging potential but that long-term safety and efficacy in healthy aging adults remain areas of active research. Baseline blood work confirming low IGF-1 is the standard starting point. Sermorelin requires a prescription from a licensed provider and is not available over the counter.
Who Should Not Use Sermorelin
A licensed provider will evaluate individual risk factors before prescribing. The following are generally considered contraindications or conditions requiring additional clinical scrutiny:
- Active malignancy or personal history of cancer — GH's pro-proliferative signaling may theoretically stimulate cell growth; sermorelin use has not been studied in active cancer populations
- Diabetes mellitus or clinically significant insulin resistance — GH counter-regulates insulin; elevated GH can worsen glycemic control in susceptible individuals
- Active intracranial lesions or a history of pituitary tumor — sermorelin's pituitary-stimulating mechanism requires clinical evaluation in this context
- Pregnancy or breastfeeding — safety in these populations has not been established
- Known hypersensitivity to sermorelin acetate, mannitol (a common excipient in compounded formulations), or any component of the formulation
- Hypothyroidism, if untreated — thyroid hormone is required for adequate GH response; providers typically evaluate thyroid status before initiating sermorelin therapy
Side Effects and Safety Considerations
The sermorelin safety profile is characterized primarily in the 1999 Prakash and Goa monograph and in GHRH class studies. Most reported adverse effects are mild, dose-dependent, and often diminish within the first weeks of use.
Common (reported in clinical studies):
- Injection-site redness, swelling, or pain — typically resolves within 30 to 60 minutes of subcutaneous administration
- Flushing — transient and generally mild; more common at higher doses
- Headache — reported in early-stage use; often resolves spontaneously
- Somnolence or drowsiness — consistent with sermorelin's sleep-promoting mechanism; generally considered favorable when timed to evening administration
Less common but reported:
- Fluid retention or peripheral edema — attributable to GH's effects on sodium and water reabsorption; monitor in individuals with cardiovascular or renal conditions
- Joint pain or stiffness (arthralgia) — associated with GH axis activity; generally dose-related and reversible on dose adjustment
- Dizziness — contact your provider if persistent
- Glucose elevation — particularly in individuals with pre-existing insulin resistance; baseline and follow-up glucose monitoring is standard
Is Sermorelin Legal?
As of April 2026, sermorelin is not FDA-approved for any indication. The original pediatric approval lapsed after the manufacturer voluntarily withdrew the product from the US market by 2008. No current FDA-reviewed clinical indication exists. Sermorelin is not available over the counter.
Sermorelin is on the FDA's Category 1 bulk drug substances list, meaning it is eligible for compounding. It may be legally compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed by a licensed provider and dispensed by a licensed 503A compounding pharmacy with a patient-specific prescription. Superpower facilitates access to compounded sermorelin through its licensed provider network and compounding pharmacy partners.
As of the 2026 WADA Prohibited List, all growth hormone secretagogues — including GHRH analogs — are prohibited in competition. Athletes subject to anti-doping testing should consult their governing body or a qualified anti-doping advisor before use.
Understanding Your Baseline Before Starting Sermorelin
A single IGF-1 reading does not tell the full story. Baseline testing establishes where your GH axis sits before therapy begins, so changes at 3 and 6 months are measurable and interpretable. IGF-1 below the age-adjusted reference range confirms that the GH axis is underperforming relative to age-matched norms. Fasting glucose and a complete metabolic panel identify metabolic risk factors that inform prescribing decisions. Without these baselines, there is no objective way to evaluate whether therapy is producing a meaningful response, or whether individual risk factors require closer monitoring.
That principle — test first, then decide — is central to Superpower's approach to preventive health: the belief that every clinical decision should be grounded in what your bloodwork actually shows, not in symptoms alone.
Frequently Asked Questions
What is the difference between sermorelin and HGH?
Sermorelin stimulates the pituitary to release growth hormone in a pulsatile, physiologically regulated pattern. Exogenous HGH delivers GH directly, bypassing the hypothalamic-pituitary feedback loop entirely. This means HGH can produce supraphysiological GH levels without a natural braking mechanism. Sermorelin preserves that feedback regulation, which limits the risk of excess GH exposure. HGH is FDA-approved for confirmed adult GH deficiency; sermorelin has no current FDA-approved adult indication and is available only through compounding.
Does sermorelin suppress natural growth hormone production?
No. Sermorelin operates by stimulating the pituitary's own GH release, not by supplying exogenous GH. Because it preserves the hypothalamic feedback loop, the body retains the ability to reduce GH output via somatostatin when levels are adequate. This physiological self-regulation distinguishes sermorelin from exogenous HGH, which can suppress the pituitary's natural output over time through negative feedback from circulating GH and IGF-1.
How long does sermorelin take to work?
IGF-1 levels typically begin to rise within several weeks of consistent use. Measurable changes in body composition, sleep quality, and recovery are generally reported at 3 to 6 months. Response varies based on baseline IGF-1 levels, pituitary responsiveness, and individual physiology. Individuals with lower baseline IGF-1 tend to show the most pronounced response.
Do sermorelin injections or troches work better?
Subcutaneous injections offer higher bioavailability and more consistent GH stimulation. Sublingual troches are a needle-free alternative with lower but sustained absorption. Clinical evidence for the GHRH class is based primarily on injectable formulations; sublingual data are more limited. The appropriate formulation depends on clinical context, patient preference, and provider assessment.
How long can you stay on sermorelin?
There is no established maximum duration for compounded sermorelin use. GHRH analog studies have evaluated therapy over periods of 26 to 52 weeks. Providers typically reassess at 3- to 6-month intervals based on IGF-1 response, symptom changes, and metabolic markers. Long-term safety in healthy aging adults is an ongoing area of research. Continued use requires periodic provider evaluation and ongoing prescription.
Is sermorelin FDA-approved?
Sermorelin was FDA-approved in 1997 for the diagnosis and treatment of idiopathic growth hormone deficiency in children. The manufacturer voluntarily withdrew the product from the US market by 2008. There is no currently FDA-approved sermorelin product. As of April 2026, sermorelin is available only as a compounded prescription through licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider.
What age should you start sermorelin?
There is no universally established minimum age for compounded sermorelin use in adults. Providers typically evaluate candidacy based on clinical presentation and biomarker findings rather than age alone. Age-related GH decline (somatopause) begins in the third decade. Many providers who prescribe sermorelin see patients in their 40s and 50s with documented low IGF-1 alongside symptoms consistent with GH decline. A baseline assessment including IGF-1 and metabolic markers is the appropriate starting point.
IMPORTANT SAFETY INFORMATION
Sermorelin is not currently FDA-approved for any indication. It was FDA-approved in 1997 for pediatric growth hormone deficiency; the manufacturer voluntarily withdrew the product by 2008 due to commercial factors. Sermorelin is on the FDA's Category 1 bulk drug substances list and may be legally compounded under Section 503A. Clinical evidence cited on this page draws primarily from the GHRH analog class (including tesamorelin trials); results may not be directly transferable to compounded sermorelin. Superpower is a technology platform; Superpower does not prescribe or dispense medications.
Contraindications: active malignancy or cancer history; diabetes or significant insulin resistance; active intracranial lesions or pituitary tumor history; pregnancy and breastfeeding; untreated hypothyroidism; known hypersensitivity to sermorelin or mannitol.
Common side effects: injection site redness/swelling, flushing, headache, drowsiness.
Less common: fluid retention or edema, joint pain (arthralgia), dizziness, glucose elevation in individuals with pre-existing insulin resistance.
All growth hormone secretagogues are on the 2026 WADA Prohibited List for use in competition.
.avif)
.avif)
.avif)
.avif)
.avif)
.jpg)
.avif)
